Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689724 | 0.85 | ACACB (0.46) | RETCHRNB4CHRNA3EIF2AK4RORC | |
| SCHEMBL31638498 | 0.81 | RET (0.43) | RETOPRK1EIF2AK4OPRM1OPRD1 | |
| SCHEMBL29182738 | 0.80 | SUV39H2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22499869 | 0.80 | SUV39H2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29690023 | 0.80 | SUV39H2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL30124591 | 0.80 | SUV39H2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29182735 | 0.80 | SUV39H2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8510780 | 0.80 | CKS1B (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4OPRK1 | |
| SCHEMBL29749147 | 0.78 | RET (0.53) | RETOPRK1EIF2AK4 | |
| SCHEMBL2065859 | 0.74 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | RET 3219/4885CHRNB2 4847/4885CHRNB4 4856/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | RET 3219/4885CHRNB2 4847/4885CHRNB4 4856/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | RET 3219/4885CHRNB2 4847/4885CHRNB4 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.